| | | Angiographic CR (1) | Selective IR (2) | Failed CR (3) | value for (1) vs. (2) | value for (1) vs. (3) | value for (2) vs. (3) |
| | Patient number, n | 249 | 317 | 34 | | | | | Age, years | 64.4 ± 11.7 | 64.4 ± 11.9 | 63.8 ± 12.8 | 0.963 | 0.762 | 0.778 | | Male sex, n (%) | 209 (83.9) | 255 (80.4) | 28 (82.4) | 0.322 | 0.806 | 1.000 | | Diabetes mellitus, n (%) | 107 (43.0) | 156 (49.2) | 14 (41.2) | 0.149 | 1.000 | 0.471 | | Hypertension, n (%) | 135 (54.2) | 187 (59.0) | 22 (64.7) | 0.267 | 0.274 | 0.584 | | Hyperlipidemia, n (%) | 104 (41.8) | 149 (47.0) | 19 (55.9) | 0.233 | 0.141 | 0.369 | | Smoking, n (%) | 108 (43.4) | 129 (40.7) | 16 (47.1) | 0.548 | 0.715 | 0.471 | | Family history of CAD, n (%) | 4 (1.6) | 4 (1.3) | 0 (0.0) | 0.736 | 1.000 | 1.000 | | Previous history of MI, n (%) | 193 (77.5) | 254 (80.1) | 25 (73.5) | 0.468 | 0.664 | 0.374 | | Previous stroke, n (%) | 8 (3.2) | 21 (6.6) | 3 (8.8) | 0.084 | 0.133 | 0.717 | | NYHA Fc | | Class I, n (%) | 112 (45.0) | 127 (40.1) | 8 (23.5) | 0.265 | 0.025 | 0.065 | | Class II, n (%) | 68 (27.3) | 83 (26.2) | 8 (23.5) | 0.775 | 0.837 | 0.839 | | Class III, n (%) | 41 (16.5) | 67 (21.1) | 8 (23.5) | 0.196 | 0.334 | 0.826 | | Class IV, n (%) | 28 (11.2) | 40 (12.6) | 10 (29.5) | 0.696 | 0.007 | 0.017 | | ACS, n (%) | 101 (40.6) | 116 (36.6) | 15 (44.1) | 0.340 | 0.713 | 0.456 | | eGFR, ml/min/1.73m2 | 71.5 ± 29.6 | 67.4 ± 26.2 | 65.0 ± 26.7 | 0.358 | 0.256 | 0.838 | | CKD stage >3, n (%) | 89 (35.7) | 132 (41.6) | 15 (44.1) | 0.165 | 0.349 | 0.855 | | LVEF, % | 32.1 ± 6.8 | 32.2 ± 7.0 | 29.1 ± 8.2 | 0.821 | 0.015 | 0.020 | | Calcified lesion, n (%) | 67 (26.9) | 81 (25.6) | 7 (20.6) | 0.773 | 0.535 | 0.678 | | Ostial lesion, n (%) | 34 (13.7) | 43 (13.6) | 3 (8.8) | 1.000 | 0.591 | 0.596 | | Bifurcation, n (%) | 26 (10.4) | 25(7.9) | 0(0.0) | 0.304 | 0.054 | 0.152 | | Chronic total occlusion, n (%) | 36 (14.5) | 35 (11.0) | 14 (41.2) | 0.250 | <0.001 | <0.001 | | Drug-eluting stenting, n (%) | 138 (55.4) | 166 (52.4) | 16 (47.1) | 0.497 | 0.366 | 0.592 | | Survival to discharge, m | 238 | 307 | 26 | | | | | Use of ACEi/ARB, n (n/m%) | 191 (80.3) | 248 (80.8) | 20 (76.9) | 0.913 | 0.617 | 0.610 | | Use of beta blocker, n (n/m%) | 215 (90.3) | 279 (90.9) | 22 (84.6) | 0.883 | 0.319 | 0.296 | | Use of MRA, n (n/m%) | 46 (19.3) | 62 (20.2) | 3 (11.5) | 0.829 | 0.433 | 0.439 |
|
|
ACEi, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CKD, chronic kidney disease; CR, complete revascularization; eGFR, estimated glomerular filtration rate; IR, incomplete revascularization; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA Fc, New York Heart Association Functional classification; RCS, residual coronary stenosis.
|
